Evidence map›Paper›PMID 41383879›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Development of amyloid-negative neuropsychological norms using GAMLSS.

Sara Rubio-Guerra, María Belén Sánchez-Saudinós, Isabel Sala, Laura Videla, Alexandre Bejanin, Ainara Estanga, Mirian Ecay-Torres, Carolina Lopez de Luis, Lorena Rami, Adrià Tort-Merino and 20 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Development of amyloid-negative neuropsychological norms using GAMLSS.Alzheimer's & dementia (Amsterdam, Netherlands)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Sara Rubio-GuerraSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.ORCID https://orcid.org/0000-0001-7652-8029
María Belén Sánchez-SaudinósSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.
Isabel SalaSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.
Laura VidelaSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.
Alexandre BejaninSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.
Ainara EstangaFundación CITA-Alzhéimer Fundazioa Centro de Investigación y Terapias Avanzadas San Sebastián Gipuzkoa Spain.
Mirian Ecay-TorresFundación CITA-Alzhéimer Fundazioa Centro de Investigación y Terapias Avanzadas San Sebastián Gipuzkoa Spain.
Carolina Lopez de LuisFundación CITA-Alzhéimer Fundazioa Centro de Investigación y Terapias Avanzadas San Sebastián Gipuzkoa Spain.
Lorena RamiCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
Adrià Tort-MerinoCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
Magdalena CastellvíAlzheimer's disease and other cognitive disorders Unit Hospital Clínic de Barcelona Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Ana PozuetaCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
María García-MartínezCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
David Gómez-AndrésHospital Universitari Vall d'Hebron Vall d'Hebron Institut de Recerca (VHIR) Barcelona Spain.
Carmen LageCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
Sara López-GarcíaCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
Pascual Sánchez-JuanCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
Mircea BalasaCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
Albert LladóCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
Miren AltunaFundación CITA-Alzhéimer Fundazioa Centro de Investigación y Terapias Avanzadas San Sebastián Gipuzkoa Spain.
Mikel TaintaFundación CITA-Alzhéimer Fundazioa Centro de Investigación y Terapias Avanzadas San Sebastián Gipuzkoa Spain.
Javier ArranzSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.
Nuole ZhuSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.
Daniel AlcoleaSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.
Alberto LleóSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.
Juan ForteaSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.
Eloy Rodríguez RodríguezCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
Raquel Sánchez-ValleCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III Madrid Spain.
Pablo Martínez-LageFundación CITA-Alzhéimer Fundazioa Centro de Investigación y Terapias Avanzadas San Sebastián Gipuzkoa Spain.
Ignacio Illán-GalaSant Pau Memory Unit, Department of Neurology IR SANT PAU, Hospital de la Santa Creu i Sant Pau Barcelona Spain.ORCID https://orcid.org/0000-0002-5418-2052

Funding

DS-ARC: A Remote Digital Cognitive Assessment for Down Syndrome-Associated Alzheimer's DiseaseR01AG081394 · NIA · WASHINGTON UNIVERSITY · PI Jason J Hassenstab · 2023 to 2026
$6.0M
The Role of Inflammation and NGF Dysfunction in the Evolution of Alzheimer Disease Pathology in Down Syndrome-RevisionRF1AG056850 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI BUSCIGLIO, JORGE A, CUELLO, A CLAUDIO · 2018 to 2020
$5.9M
Clinical trials to prevent Alzheimer's Disease in Down SyndromeR61AG066543 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RAFII, MICHAEL S · 2019 to 2020
$5.6M
Tau pathology in Down syndrome and Alzheimer'sRF1AG061566 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER, MARGITTAI, MARTIN · 2019 to 2019
$3.4M
Bilingual Factors Associated with Cognitive Reserve and Linguistic Resilience in Hispanics with Primary Progressive AphasiaR01AG080470 · NIA · UNIVERSITY OF TEXAS AT AUSTIN · PI Stephanie M Grasso · 2023 to 2026
$2.8M
Biological Correlates of Alzheimer in Down Syndrome.R21AG056974 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER · 2017 to 2018
$414k
NIA NIH HHS R01 AG080470NIA NIH HHS R01 AG081394NIA NIH HHS R21 AG056974NIA NIH HHS R61 AG066543NIA NIH HHS RF1 AG056850NIA NIH HHS RF1 AG061566
6 · The paper itself

Abstract

introductionRecent research has suggested increased sensitivity of Alzheimer's disease (AD)-negative neuropsychological norms; concurrently, generalized additive models for location, scale, and shape (GAMLSS) have emerged as a promising alternative to traditional norming approaches. Here, we developed amyloid β-negative (Aβ-) next-generation norms (NGN) for a comprehensive neuropsychological battery using GAMLSS.

methodsWe included

resultsAge-, education-, and sex-adjusted DISCUSSION: NGN may improve the detection of objective cognitive impairment in clinical and research settings. Highlights: Brain amyloid β (Aβ) is associated with poorer performance in cognitively normal individuals.We provide GAMLSS-based Aβ-negative norms for 14 neuropsychological measures.Age, education, and often sex significantly influence cognitive performance.An online calculator for the demographically adjusted

Indexed as

Alzheimer's diseaseamyloid βGAMLSSneuropsychological normsnormative data

Identifiers

PMID41383879
PMCPMC12689457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.